focus -WSS

focus

author：comprehensive 2025-09-06 02:14:02 - browse：22

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Designating disabled people as health disparity population is crucial

WSS

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Case highlights the risks of experimental stem cell therapy

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Wearables generate powerful data but its not useful to doctors, yet

GSK to buy asthma

Military medical care influenced by rank and race, new study finds

entertainment

focus

leisure time

New air purifier tech could be key to improving indoor air quality

When prostate cancer spreads, where it goes matters

Drug repurposing or repositioning? The language matters

Designating disabled people as health disparity population is crucial

Alkermes shareholders re

Addiction experts warn against a second 'war on drugs'

Anesthesiologist group: stop taking Ozempic before surgery

Data integrity in scientific journals requires "effort" by publishers, institutions

Jerome Adams on the need for new antivirals for Covid

HIV vaccine remains elusive. Immunologists keep trying new ideas

explore

Anxious about a speech? A startup wants you to pop a minty cardiac drug

How I ended up pumping milk in a bathroom stall at JPM 2024

HIV vaccine remains elusive. Immunologists keep trying new ideas

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

With measles on the rise, a personal story of a devastating disease

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

hotspot

explore

Wikipedia

knowledge